VivoSim Labs (VIVS) Construction in Progress (2015 - 2019)

VivoSim Labs (VIVS) posted quarterly Construction in Progress of $47000.0 for Q1 2019, down 9.62% quarter-over-quarter from $52000.0 in Q1 2016.

VivoSim Labs (VIVS) Construction in Progress (2015 - 2019) Analysis & Trends

VivoSim Labs' Construction in Progress history runs 3 years deep, the most recent figure standing at $47000.0 for Q1 2019.

In Q1 2019, Construction in Progress changed N/A year-over-year to $47000.0; the TTM figure through Mar 2019 stood at $47000.0 (changed N/A YoY), while the FY2019 annual figure was $47000.0, changed N/A from the prior year.
Construction in Progress for Q1 2019 stood at $47000.0, down from $52000.0 in the prior quarter.
The five-year high for Construction in Progress was $529000.0 in Q1 2015, with the low at $47000.0 in Q1 2019.
The 3-year median for Construction in Progress is $52000.0 (2016), against an average of $209333.3.
Peak annual rise in Construction in Progress reached 90.17% in 2016, while the deepest fall reached 90.17% in 2016.
VivoSim Labs' Construction in Progress stood at $529000.0 in 2015, then tumbled by 90.17% to $52000.0 in 2016, then retreated by 9.62% to $47000.0 in 2019.
Business Quant data shows VIVS's Construction in Progress at $47000.0 in Q1 2019, $52000.0 in Q1 2016, and $529000.0 in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Vertex Pharmaceuticals	138.79 Bn	130.93 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.99 Bn	78.00 Bn	3.93 Bn	-
3	Argenx Se	65.26 Bn	60.07 Bn	1.37 Bn	-
4	Moderna	56.04 Bn	50.91 Bn	52.00 Mn	-
5	BeOne Medicines	42.05 Bn	36.95 Bn	1.53 Bn	152.67 Mn
6	Alnylam Pharmaceuticals	31.71 Bn	28.40 Bn	992.69 Mn	-
7	BioNTech SE	27.66 Bn	9.26 Bn	668.28 Mn	-
8	Insmed	27.50 Bn	26.33 Bn	358.27 Mn	-
9	Royalty Pharma	27.35 Bn	26.52 Bn	-	-
10	VivoSim Labs	1.47 Mn	1.47 Mn	-	-

Download Data